These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 20698226)
1. The clinical and histological characteristics and outcomes of drug induced chronic liver injury after removing causative drugs. Hou FQ; Wang TL; Liu X; Huo N; Wang GQ Hepatogastroenterology; 2010; 57(99-100):554-61. PubMed ID: 20698226 [TBL] [Abstract][Full Text] [Related]
2. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Romeo R; Del Ninno E; Rumi M; Russo A; Sangiovanni A; de Franchis R; Ronchi G; Colombo M Gastroenterology; 2009 May; 136(5):1629-38. PubMed ID: 19208358 [TBL] [Abstract][Full Text] [Related]
3. [Study on the natural history of chronic hepatitis B]. Wu G; Zhou W; Zhao Y; Guo S; Wang Z; Zou S; Zhang Q; Ren H; Huang A; Zhang D Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):46-8. PubMed ID: 11856503 [TBL] [Abstract][Full Text] [Related]
4. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Andrade RJ; Lucena MI; Kaplowitz N; García-Muņoz B; Borraz Y; Pachkoria K; García-Cortés M; Fernández MC; Pelaez G; Rodrigo L; Durán JA; Costa J; Planas R; Barriocanal A; Guarner C; Romero-Gomez M; Muņoz-Yagüe T; Salmerón J; Hidalgo R Hepatology; 2006 Dec; 44(6):1581-8. PubMed ID: 17133470 [TBL] [Abstract][Full Text] [Related]
5. [Histological characteristics of chronic hepatitis C in biopsy material]. Jármay K; Karácsony G; Ozsvár Z; Nagy I; Schaff Z; Lonovics J Orv Hetil; 1998 Aug; 139(33):1955-60. PubMed ID: 9734212 [TBL] [Abstract][Full Text] [Related]
6. [Clinico-prognostic significance of partial seroconversion in chronic viral hepatitis B follow-up. Wartenbert Study (1974-1994), II]. Ohlen I; Liegl JM; Selmair H Leber Magen Darm; 1995 Dec; 25(6):259-62. PubMed ID: 8577215 [TBL] [Abstract][Full Text] [Related]
7. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation]. Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723 [TBL] [Abstract][Full Text] [Related]
8. Biochemical and histologic evaluation of recurrent hepatitis C following orthotopic liver transplantation. Shiffman ML; Contos MJ; Luketic VA; Sanyal AJ; Purdum PP; Mills AS; Fisher RA; Posner MP Transplantation; 1994 Feb; 57(4):526-32. PubMed ID: 8116036 [TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911 [TBL] [Abstract][Full Text] [Related]
10. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. Cotler SJ; Taylor SL; Gretch DR; Bronner MP; Rizk R; Perkins JD; Carithers RL Am J Gastroenterol; 2000 Mar; 95(3):753-9. PubMed ID: 10710070 [TBL] [Abstract][Full Text] [Related]